Title: A Theory on Using CD36 as an Immune Targeting Portal in Cancer
Title: A Theory on Using CD36 as an Immune Targeting Portal in Cancer — Looking for Scientific Feedback
I'm not a researcher. I'm someone who lost my mother to breast cancer and is currently watching my uncle fight stage 4 melanoma. Out of that pain I've spent a lot of time reading, thinking, and developing a concept I can't stop coming back to. I'm posting here because I want honest scientific feedback — not validation. If this has holes, I want to know. If any part is worth exploring, I want it to reach someone who can actually test it.
The Core Idea
Most cancer treatment tries to kill cancer cells directly. My concept takes a different angle:
What if we could make cancer cells betray their own location — forcing them to become irresistible targets for the immune system?
The Mechanism
Many aggressive cancers — melanoma included — overexpress CD36, a receptor involved in fatty acid uptake. Tumors use CD36 to fuel their rapid growth by greedily absorbing lipids from their environment.
My proposal is to exploit that greed.
Engineer a lipid-based payload — potentially a modified lipid nanoparticle, similar in concept to mRNA vaccine delivery vehicles — that CD36-overexpressing cancer cells preferentially absorb. The payload would be designed to do one or both of the following once internalized:
Force antigen presentation — deliver an immunogenic peptide that gets processed and displayed on MHC-I molecules, essentially making the cancer cell wave a flag that killer T-cells can recognize and respond to.
Trigger immunogenic cell death — cause the cancer cell to die in a way that's immunologically "loud," releasing danger signals (DAMPs) that recruit dendritic cells and prime a broader T-cell response against the tumor.
The cancer cell's own metabolic greed becomes the mechanism of its unmasking.
Why CD36 Specifically
Overexpressed in aggressive cancers including melanoma, breast cancer, and oral squamous cell carcinoma
Already linked to metastasis and immune evasion
Healthy cells express CD36 at lower levels, potentially offering a therapeutic window
Using it as a delivery portal rather than simply blocking it preserves its role as a targeting mechanism rather than a blunt inhibition strategy
What a First Experiment Might Look Like
A relatively simple proof of concept could be run in cell culture:
Take CD36-overexpressing cancer cells
Expose them to an engineered lipid payload carrying an immunogenic peptide
Measure whether MHC-I antigen presentation increases
Co-culture with T-cells and measure cytotoxic response
No human trials. Just a starting signal.
What I'm Looking For
I'm not looking for credit. I just want to know if this is worth pursuing. If someone in a lab finds this interesting enough to explore, that's everything. If there's a fatal flaw in the mechanism I'm missing, I genuinely want to know that too.
Is any part of this scientifically viable?
Any replies are greatly appreciated